Merck (NYSE:MRK) recently reported its Q4 2018 earnings, which were slightly below our estimates. The company's top line and bottom line grew in mid-single-digits in Q4, led by a continued ramp up in Keytruda, and Gardasil sales. Looking forward, we continue to believe that Keytruda, along with ...
Merck (NYSE:MRK) recently reported its Q4 2018 earnings, which were slightly below our estimates. The company's top line and bottom line grew in mid-single-digits in Q4, led by a continued ramp up in Keytruda, and Gardasil sales. Looking forward, we continue to believe that Keytruda, along with ...
Share this Article
Recommended